What was the overall market valuation of the China pain relief-medication market in 2024?

The overall market valuation was $8.07 Billion in 2024. Read More

What is the projected market valuation for the China pain relief-medication market by 2035?

The projected valuation for 2035 is $17.36 Billion. Read More

What is the expected CAGR for the China pain relief-medication market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 7.22%. Read More

Which segment is projected to have the highest growth in the China pain relief-medication market?

The Adjuvant Analgesics segment is projected to grow from $3.07 Billion to $6.36 Billion. Read More

What are the key players in the China pain relief-medication market?

Key players include Johnson & Johnson, Pfizer, Bayer, and GlaxoSmithKline. Read More

How does the valuation of Opioids compare to that of Acetaminophen in 2024?

In 2024, Opioids were valued at $1.0 Billion, while Acetaminophen was valued at $1.5 Billion. Read More

What is the projected valuation for the Tablets segment by 2035?

The Tablets segment is projected to reach $5.25 Billion by 2035. Read More

What therapeutic area is expected to see the highest valuation in the China pain relief-medication market?

Cancer Pain is expected to see a valuation increase from $2.82 Billion to $5.88 Billion. Read More

What is the projected growth for the Injectable route of administration by 2035?

The Injectable route is projected to grow from $2.03 Billion to $4.45 Billion by 2035. Read More

How does the market for Topical formulations compare to that of Liquid formulations in 2024?

In 2024, the Topical formulations were valued at $2.82 Billion, while Liquid formulations were valued at $1.21 Billion. Read More

China Pain Relief Medication Market

ID: MRFR/HC/49339-HCR 200 Pages Nidhi Mandole Last Updated: September 17, 2026

China Pain Relief Medication Market Research Report: Size, Share, Trend Analysis By Medication Type (Non-Steroidal Anti-Inflammatory Drugs, Acetaminophen, Opioids, Adjuvant Analgesics), By Formulation Type (Tablets, Capsules, Liquid, Topical), By Route of Administration (Oral, Topical, Injectable, Transdermal) and By Therapeutic Area (Chronic Pain, Acute Pain, Postoperative Pain, Cancer Pain) - Growth Outlook & Industry Forecast 2025 To 2035

China Pain Relief Medication Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.22%

2024 Market Size$ 8.07 Billion

2025 Market Size$ 8.65 Billion

2035 Market Size$ 17.36 Billion

Key Players

Johnson & Johnson

Pfizer

Bayer

GlaxoSmithKline

AbbVie

AstraZeneca

Trends

Rising Demand for Non-Opioid Alternatives
Increased Focus on Personalized Medicine
Expansion of Over-the-Counter Options

Opportunities

Growing Aging Population
Increased Health Awareness
Rising Incidence of Chronic Diseases

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Billion)
  1. 4.1.1 Non-Steroidal Anti-Inflammatory Drugs
  2. 4.1.2 Acetaminophen
  3. 4.1.3 Opioids
  4. 4.1.4 Adjuvant Analgesics
2. 4.2 Life Sciences, BY Formulation Type (USD Billion)
  1. 4.2.1 Tablets
  2. 4.2.2 Capsules
  3. 4.2.3 Liquid
  4. 4.2.4 Topical
3. 4.3 Life Sciences, BY Route of Administration (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Topical
  3. 4.3.3 Injectable
  4. 4.3.4 Transdermal
4. 4.4 Life Sciences, BY Therapeutic Area (USD Billion)
  1. 4.4.1 Chronic Pain
  2. 4.4.2 Acute Pain
  3. 4.4.3 Postoperative Pain
  4. 4.4.4 Cancer Pain
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bayer (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GlaxoSmithKline (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AbbVie (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Teva Pharmaceutical Industries (IL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY TYPE
3. 6.3 CHINA MARKET ANALYSIS BY FORMULATION TYPE
4. 6.4 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 LIFE SCIENCES, BY FORMULATION TYPE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
16. 6.16 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
18. 6.18 LIFE SCIENCES, BY THERAPEUTIC AREA, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

China Pain Relief Medication Market Segmentation

China Pain Relief Medication Market By Type (USD Billion, 2025-2035)

Non-Steroidal Anti-Inflammatory Drugs
Acetaminophen
Opioids
Adjuvant Analgesics

China Pain Relief Medication Market By Formulation Type (USD Billion, 2025-2035)

Tablets
Capsules
Liquid
Topical

China Pain Relief Medication Market By Route of Administration (USD Billion, 2025-2035)

Oral
Topical
Injectable
Transdermal

China Pain Relief Medication Market By Therapeutic Area (USD Billion, 2025-2035)

Chronic Pain
Acute Pain
Postoperative Pain
Cancer Pain

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”